Compare Cardinal Health Inc (CAH) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Cardinal Health Inc trades at $228.8 (market cap $53.89B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.6. The key difference: Cardinal Health Inc pays a 0.89% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| CAH | VCIT | |
|---|---|---|
Market Cap | $53.89B | — |
Sector | Health | Fixed Income |
52-Week High | $239.71 | $84.82 |
52-Week Low | $146.04 | $81.45 |
Enterprise Value | $58.87B | — |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $81.45, down 0.44% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The fund maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective option for intermediate-duration corporate bond exposure. Recent dividend payments of $0.33-$0.34 per share demonstrate consistent income distribution to investors.
The outlook remains balanced with VCIT offering attractive yield characteristics amid moderate duration risk. Key considerations include interest rate sensitivity and corporate credit quality, with the fund providing diversification across 2,000+ investment-grade bonds. Market sentiment appears cautiously optimistic given the fund's low-cost structure and steady income profile in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
